U.S. markets closed
  • S&P 500

    4,519.63
    +33.17 (+0.74%)
     
  • Dow 30

    35,457.31
    +198.70 (+0.56%)
     
  • Nasdaq

    15,129.09
    +107.28 (+0.71%)
     
  • Russell 2000

    2,275.91
    +8.07 (+0.36%)
     
  • Crude Oil

    83.01
    +0.05 (+0.06%)
     
  • Gold

    1,769.40
    -1.10 (-0.06%)
     
  • Silver

    23.71
    -0.17 (-0.72%)
     
  • EUR/USD

    1.1636
    +0.0018 (+0.15%)
     
  • 10-Yr Bond

    1.6350
    +0.0510 (+3.22%)
     
  • GBP/USD

    1.3793
    +0.0066 (+0.48%)
     
  • USD/JPY

    114.3580
    +0.0460 (+0.04%)
     
  • BTC-USD

    64,174.90
    +2,434.41 (+3.94%)
     
  • CMC Crypto 200

    1,481.22
    +17.87 (+1.22%)
     
  • FTSE 100

    7,217.53
    +13.70 (+0.19%)
     
  • Nikkei 225

    29,215.52
    +190.06 (+0.65%)
     

FDA panel recommends Pfizer’s COVID-19 booster for 65 and older, but not for the general public

FDA panel recommends Pfizer’s COVID-19 booster for 65 and older, but not for the general public
In this article:
  • Oops!
    Something went wrong.
    Please try again later.
  • Oops!
    Something went wrong.
    Please try again later.

A group of advisors to the Food and Drug Administration on Friday reframed a proposed approval of BioNTech and Pfizer's COVID-19 booster for the general population, and it instead recommended authorization of an additional dose of the vaccine to people at least 65 years old and those at high risk for severe disease.